We are:

  • A Biotechnology Company Specializing in Human Vaccines
  • Creating, Developing, Manufacturing & Testing Innovative AIDS Vaccines
  • Conducting Multiple Site Phase 2 Human Clinical Vaccine Trial

Our AIDS Vaccines:

  • Are Designed for Predominant AIDS Virus Subtypes
  • Use DNA & Viral Vector Technologies
  • Satisfactorily Completed Phase 1 Human Clinical Trial Testing
  • Have Been Proven Safe & Have Demonstrated Ability To Stimulate Immune Responses

Key Market Factors:

  • Vaccines Are The Most Cost Effective Way to Combat Infectious Disease
  • Large Global AIDS Vaccine Market Is Estimated To Be More Than $4 Billion
  • Customer Base Includes All Ages, Gendors, Races, Nationalities, Geographical Regions

23 June 2009

Results from Annual Shareholders' Meeting Announced

Read full story (pdf) »
Download presentation (pdf) »

18 June 2009

GeoVax Signs HIV/AIDS Vaccine Proposal with Cook County, IL

Read full story (pdf) »

20 February 2009

Injections Start for GeoVax Phase 2a Human Vaccine Trial

Read full story (pdf) »

10 February 2009

WEBCAST: GeoVax Labs at BIO CEO & Investor Conference 2009

View webcast »

S&P

GeoVax Fact Sheet (pdf)